Highlights
- Imugene’s oncolytic virotherapy platform and B cell immunotherapy are to be presented at the ESMO Congress.
- ESMO Congress is amongst the most influential oncology platforms globally.
- The oncology event is to be held in Madrid during 20-24 October 2023.
ASX-listed clinical-stage immune-oncology company Imugene Limited (ASX: IMU) shared that its cancer therapy platforms HER - Vaxx and CHECKVacc will be featured at the ESMO (European Society for Medical Oncology) Congress. The event will take place in Madrid on 20-24 October 2023.
The ESMO Congress is one of the prominent oncology platforms for journalists, healthcare industry representatives, patient advocates, clinicians, researchers and journalists.
Imugene will feature in the following poster sessions:
HER - Vaxx is a B cell immunotherapy, and CHECKVacc is a CF33 oncolytic virotherapy being developed by Imugene.
Shares up ~4%
Following the update, the share price of IMU increased by 3.191% to trade at AU$0.097 per share at the time of writing on 24 July 2023.